Biomedical Engineering Reference
In-Depth Information
[27] Schenerman MA. Defining critical quality attributes and linking to QbD and molecular
structure. In: Rathore AS, Mhatre R, editors. Quality by Design for Biopharmaceuticals:
Perspectives and Case Studies. Wiley Interscience; 2009.
[28] Kourti T. Process analytical technology and multivariate statistical process control: wellness
index of product and process—part 3. J Process Anal Technol 2006;3:18-24.
[29] PDA. Technical Report 42, (TR42) Process Validation of Protein Manufacturing, 2005.
[30] Senger RS, Karim MN. Effect of shear stress on intrinsic CHO culture state and
glycosylation of recombinant tissue-type plasminogen activator protein. Biotechnol Prog
2003;19:1199-1209.
[31] Wong DC, Wong KT, Nissom PM, Heng CK, Yap MG. Targeting early apoptotic genes in
batch and fed-batch CHO cell cultures. Biotechnol Bioeng 2006;95:350-361.
[32] Delvigne F, Lejeune A, Destain J, Thonart P. Stochastic models to study the impact of mixing
on a fed-batch culture of Saccharomyces cerevisiae. Biotechnol Prog 2006;22:259-269.
[33] Kourti T. The process analytical technology initiative and multivariate process analysis,
monitoring and control. Anal Bioanal Chem 2006;384:1043-1048.
[34] U.S. FDA. Frequently Asked Questions About Therapeutic Biological Products: Question
10, 2006. http://www.fda.gov/cder/biologics/qa.htm.
[35] U.S. FDA. FDAGuidance Concerning Demonstration of Comparability of Human Biologi-
cal Products, Including Therapeutic Biotechnology-Derived Products, 1996. http://www.fda.
gov/cder/guidance/compare.htm.
[36] Eriksson E, Johansson E, Kattaneh-Wold N, Wikstrom C, Wold S. Design of Experiments,
Principles and Applications. Umea, Sweden: Umetrics Academy; 2000.
[37] Lewis GA, Mathieu D, Phan-Tan-Luu R. Pharmaceutical Experimental Design. New York:
Informa Healthcare; 2007.
[38] McDermott RE, Mikulak RJ, BeauregardMR. The Basics of FMEA. NewYork: Productivity
Press; 1996.
[39] Stamatis DH. Failure Mode and Effects Analysis: FMEA fromTheory to Execution. 2nd ed.
Milwaukee, WI: ASQ Quality Press; 2003.
[40] Seely JF, Seely RJ. A rational step-wise approach to process characterization. BioPharm Int
2003;16:24-34.
[41] Kelley BD. Establishing process robustness using designed experiments. In: Sofer G,
Zabriskie DW, editors. Biopharmaceutical Process Validation. New York: Marcel Dekker;
2000. p 29-59.
[42] Kelley BD, Jennings P, Wright R, Briasco C. Demonstrating process robustness for
chromatographic purification of a recombinant protein. BioPharm Int 1997;10:36-47.
[43] U.S. FDA. Guidance for Industry: Quality Systems Approach to Pharmaceutical CGMP
Regulations, 2006.
[44] ICH. Q10 Pharmaceutical Quality System Step 2, 2007. (step 4, 6/4/2008, http://www.ich.
org/cache/compo/363-272-1.html#Q10).
[45] Johanson JR. A rolling theory for granular solids. J Appl Mech 1965;32:842-848.
[46] Roberts RJ, Rowe RC, York P. The relationship between the fracture properties, tensile
strength and critical stress intensity factor of organic solids and their molecular structure.
Int J Pharm 1995;125:157-162.
[47] Chen J, Yang T, Cramer SM. Prediction of protein retention times in gradient hydrophobic
interaction chromatographic systems. J Chromatogr A 2008;1177:207-214.
